Jane Street’s Janux Therapeutics JANX Stock Holding History

Jane Street’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$803K	Sell	57,800 -2,200	-4%	-$30.2K	﹤0.01%	6964
2025 Q4	$828K	Buy	+60,000	New	+$1.41M	﹤0.01%	6544
2025 Q3	–	Sell	-10,800	Closed	-$249K	–	11288
2025 Q2	$249K	Sell	10,800 -20,100	-65%	-$530K	﹤0.01%	8164
2025 Q1	$834K	Sell	30,900 -19,300	-38%	-$728K	﹤0.01%	5908
2024 Q4	$2.69M	Buy	+50,200	New	+$2.66M	﹤0.01%	3622
2024 Q3	–	Sell	-6,800	Closed	-$285K	–	10006
2024 Q2	$285K	Buy	+6,800	New	+$319K	﹤0.01%	7879

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jane Street's JANX Position: Q1 2026 in Review

Jane Street reduced its Janux Therapeutics (JANX) stake by 53% in Q1 2026, selling an estimated $3.96M and leaving 251,740 shares worth $3.5M. The position accounts for ﹤0.01% of the portfolio, ranked #4080.

Jane Street first reported a position in JANX in Q4 2021 and has held it in 10 quarters since. The position peaked at $7.46M in Q4 2025. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

Jane Street held 251,740 shares of Janux Therapeutics worth $3.5M as of Q1 2026.
Jane Street sold 288,493 Janux Therapeutics shares in Q1 2026, an estimated $3.96M.
Janux Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #4080 holding.
Jane Street first reported a position in Janux Therapeutics in Q4 2021 and has held it in 10 quarters since.
Jane Street's Janux Therapeutics position peaked at $7.46M in Q4 2025.
190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.